FGEN — Fibrogen Cashflow Statement
0.000.00%
Last trade - 00:00- $33.69m
- $115.38m
- $29.62m
- 32
- 34
- 75
- 44
Annual cashflow statement for Fibrogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -189 | -290 | -294 | -284 | -47.6 |
| Depreciation | |||||
| Non-Cash Items | 74.2 | 133 | 66.7 | 76.7 | 22.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 175 | 60.1 | 70.4 | -117 | -115 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 81.6 | -82.2 | -146 | -315 | -138 |
| Capital Expenditures | -3.99 | -30.2 | -38.7 | -2.52 | -0.266 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 456 | -397 | 128 | 156 | 126 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 452 | -427 | 89.1 | 154 | 126 |
| Financing Cash Flow Items | -11.5 | -7.37 | -6.62 | -0.237 | -0.354 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.3 | -0.563 | 46.8 | 123 | -0.255 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 552 | -507 | -15.5 | -42 | -11.5 |